It has been reported that IGFBP-3 binds to a nuclear receptor, 9-cis retinoic acid receptor-alpha (RXR-), which interacts with peroxisome proliferator activated receptor-gamma (PPAR-), a nuclear protein involved in the regulation of glucose and lipid metabolism [175, 176]
It arises from the same core disturbances, namely central obesity, insulin resistance, and dyslipidemia and shares overlapping pathophysiology with other MetS features (157)
The full deal structure, the lead asset, and what it means for AstraZeneca's obesity pipeline is broken down on www.lifesciencedaily.news #AstraZeneca #Obesity #GLP1 #WeightManagement #Pharma #DrugDevelopment #Biopharma #LifeSciences #CSPC #ChinaPharma #Licensing To view or add a comment, sign in The obesity-diabetes drug market has emerged as one of the pharmaceutical industry's most lucrative and competitive segments, with leading companies generating tens of billions in annual revenue
By reducing oxidative stress, it keeps your skin clear and free from breakouts